MatthewAnthonyMaurerMD

Oncology • New York, NY

Breast Cancer, Hematologic Oncology

Assistant Professor, Medicine, Columbia University College of Phys & Surg

Join to view full profile

Dr. Maurer is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Maurer's full profile

Already have an account?

Office
1130 Saint Nicholas Ave
Room 217c
New York, NY 10032
Phone+1 212-851-4761

Fax+1 212-851-4572

Education & Training

New York Presbyterian Hospital (Cornell Campus)Fellowship, Hematology and Medical Oncology, 2004 - 2008
New York Presbyterian Hospital (Columbia Campus)Residency, Internal Medicine, 2001 - 2004
Icahn School of Medicine at Mount SinaiClass of 2001

Certifications & Licensure

NY State Medical License 2002 - 2026

Clinical Trials

Study of CoQ10 During One Cycle of Doxorubicin Treatment for Breast Cancer Start of enrollment: 2009 Sep 01
Completed
Phase 1
Study of Temsirolimus, Erlotinib and Cisplatin in Solid Tumors Start of enrollment: 2009 Sep 01
Completed
Phase 1
Electro-acupuncture for the Prevention of Taxane Induced Myalgias and Neuropathy Start of enrollment: 2010 Dec 01
Completed
Not Applicable
Study of Erlotinib and Metformin in Triple Negative Breast Cancer Start of enrollment: 2012 Jul 01
Completed
Phase 1
Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer Start of enrollment: 2013 Mar 07
Completed
Phase 2
Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy Start of enrollment: 2012 Oct 01
Completed
Phase 2
Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer Start of enrollment: 2014 Jan 15
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

37 citations
Electrophysiological Manifestations of Cardiac Amyloidosis: JACC: CardioOncology State-of-the-Art Review.
Jack Hartnett, Wael A. Jaber, Matthew Maurer, Brett W. Sperry, Mazen Hanna
JACC. Cardiooncology. 2021-10-01
144 citations
Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/ PTEN mutation
Yan Xing, Nan Lin, Matthew A. Maurer, Huiqin Chen, Armeen Mahvash
Breast Cancer Research. 2019-07-05
12 citations
PHLDA2 is a key oncogene-induced negative feedback inhibitor of EGFR/ErbB2 signaling via interference with AKT signaling.
Xiaoqi Wang, Guangyuan Li, Sanjay Koul, Rieko Ohki, Matthew Maurer
Oncotarget. 2018-05-18

Abstracts/Posters

Vulnerable Elders Survey-13 (VES-13) Predicts 1-Year Mortality Risk in Newly Diagnosed Non-Hodgkin Lymphoma (NHL)
Matthew J. Maurer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Press Mentions

Sickle Cell Cure Will Be Cost-Effective if Health Disparities Considered -Study FindsDecember 13th, 2022
Research Exposes Inequities in Health Care Access and Delivery for Blood DisordersDecember 10th, 2022
Father and Son Chiropractors Re-Brand to Offer Backbone for Better HealthNovember 29th, 2022
Join now to see all